RT Journal Article
SR Electronic
T1 Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2679
OP 2682
VO 37
IS 5
A1 WOONG BAE JI
A1 JUN WON UM
A1 JE SEOCK RYU
A1 KWANG DAE HONG
A1 JUNG SIK KIM
A1 BYUNG WOOK MIN
A1 SUNG YEOP JOUNG
A1 JU HAN LEE
A1 YOUNG SIK KIM
YR 2017
UL http://ar.iiarjournals.org/content/37/5/2679.abstract
AB Aim: To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy. Patients and Methods: Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay. Results: Fifty-one patients (57.3%) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemo-sensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups. Conclusion: A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better disease-free survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/leucovorin chemotherapy.